Related Experiment Video
Updated: Jan 18, 2026
06:02
Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
Published on: November 28, 2025
389
Alexander's Disease: Potential Drug Targets and Future Directions
Emily Zavala1, Tahl Zimmerman2
1Biomedical Sciences Program, Department of Physician Assistant Studies, High Point University, High Point, NC, USA. ezavala@highpoint.edu.
Molecular Neurobiology
|May 31, 2025
Summary
Alexander's disease, a rare fatal neurodegenerative disorder, involves GFAP gene issues. This review explores potential drug targets to downregulate GFAP, offering new therapeutic avenues beyond gene knockout.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Alexander's disease (AxD) is a rare, fatal neurodegenerative disorder.
- It is characterized by glial fibrillary acidic protein (GFAP) gene upregulation and Rosenthal fiber formation.
- GFAP is a marker for mature astrocytes, and its dysregulation leads to reactive astrogliosis, implicated in neurodegeneration.
Purpose of the Study:
- To review potential therapeutic targets for Alexander's disease.
- To explore drug targets impacting GFAP gene expression.
- To identify alternative treatments that downregulate GFAP, considering its neuroprotective role.
Main Methods:
- Literature review of potential drug targets.
- Exploration of pathways like STAT3, GDNF, NF-kB, LCN-2, and LPS.
- Analysis of current treatment strategies, including GFAP gene knockout.
Main Results:
- Several drug targets (STAT3, GDNF, NF-kB, LCN-2, LPS pathway) show potential for modulating GFAP expression.
- These targets are also being investigated in other neurodegenerative diseases.
- Current clinical trials focus on GFAP gene knockout, which may negate GFAP's beneficial roles.
Conclusions:
- Targeting pathways that modulate GFAP expression offers a promising therapeutic strategy for Alexander's disease.
- Downregulating GFAP, rather than eliminating it, may preserve its neuroprotective functions.
- Further research into these targets could lead to novel treatments for this rare disorder.
Related Concept Videos
01:26Targets for Drug Action: Overview
10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
01:26Drug Discovery: Overview
11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
01:24Principles of Drug Action
8.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
8.2K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827